ArriVent BioPharma (AVBP) investor relations material

Executive summary

• Positive interim data for firmonertinib in EGFR-mutant NSCLC, with pivotal Phase 3 ALPACCA study to begin enrollment in 2H 2025 and FURVENT Phase 3 top-line data expected early 2026.

• First patient dosed in Phase 1 study for ARR-217, a CDH17-targeted ADC, in gastrointestinal tumors; expanded pipeline through new licensing agreements and collaborations.

• No product revenue to date; operations funded by equity offerings and collaborations.

Financial highlights

• Net loss of $31.4 million for Q2 2025 and $95.8 million for the six months ended June 30, 2025, both up year-over-year.

• Research and development expenses rose to $27.7 million in Q2 2025 and $89.0 million for the six months, driven by pipeline expansion and a $40 million upfront payment to Lepu.

• Cash, cash equivalents, and marketable securities totaled $254.5 million as of June 30, 2025, excluding $81.1 million raised in July 2025.

• Net cash used in operations was $94.1 million for the six months ended June 30, 2025, up from $37.7 million in 2024.

Outlook and guidance

• Cash and marketable securities, plus $81.1 million from July 2025 public offering, expected to fund operations for at least 12 months and potentially through mid-2027.

• Anticipates continued increases in R&D and G&A expenses as pipeline advances and headcount grows.

• Enrollment for pivotal ALPACCA Phase 3 study in EGFR PACC mutant NSCLC anticipated in 2H 2025; FURVENT Phase 3 top-line data projected for early 2026.